Patient guide · Reviewed 2026-07-30
Breast triple assessment, the single-visit combination of clinical, imaging and needle biopsy for breast lumps.
A one-stop breast clinic combines expert clinical examination, imaging (mammography and/or ultrasound) and, where indicated, image-guided core biopsy — with a same-day plan.
Key facts
- 01
Definition
Clinical breast exam, imaging and image-guided needle biopsy delivered in a single visit.
- 02
Same-day pathway
A one-stop model — most patients receive assessment, imaging and, where indicated, biopsy on the same day.
- 03
Age-adapted imaging
Ultrasound alone under 40; mammogram plus ultrasound from 40 onward. MRI in selected cases.
- 04
Image-guided biopsy
Core biopsy performed under ultrasound guidance, or stereotactic guidance for microcalcifications.
- 05
Fast-track results
Histology reported within 7–10 days, with a multidisciplinary plan to follow.
- 06
NHS and private routes
Two-week wait NHS pathway for suspected cancer, or a same-week private one-stop clinic.
How it works
From consultation to MDT — what happens, in order.
A one-stop breast clinic condenses seven distinct steps into a single visit, with structured multidisciplinary review at the end.
Phase 1 · Before
Consultation and examination
Phase 2 · On the day
Imaging and biopsy
Phase 3 · After
MDT and plan
- 01
Before
Breast-clinic consultation
History, risk factors and symptom timeline reviewed by a consultant breast surgeon or clinician.
- 02
Before
Clinical breast examination
Structured inspection and palpation of both breasts and axillae, documenting the lump’s size, mobility and skin changes.
- 03
On the day
Ultrasound of the lump
High-frequency ultrasound characterises the lesion — cystic vs solid, margins, vascularity and axillary nodes.
- 04
On the day
Mammogram if aged 40+
Two-view digital mammography added for women 40 and over, with tomosynthesis where available.
- 05
On the day
Image-guided core biopsy if indicated
Local anaesthetic, ultrasound or stereotactic guidance, and multiple cores for histology and receptor status.
- 06
On the day
MRI in specific cases
Breast MRI added for BRCA carriers, dense breasts, silicone implants or discordant triple-assessment findings.
- 07
After
Structured MDT review of results
Radiology, pathology and surgery discuss the case at the breast MDT before a management plan is agreed with you.
Typical end-to-end: 7–10 days to final histology. Urgent NHS pathway: within two weeks.
What it shows
The diagnoses a triple assessment confirms — or rules out.
Triple assessment answers a specific question — is this breast lump benign, high-risk, or malignant, and what does that mean for you.
-
Benign cyst
A simple fluid-filled sac — the commonest cause of a discrete breast lump in women 35–50.
-
Fibroadenoma
A benign, mobile, well-defined lesion typical of women in their 20s and 30s.
-
Complex sclerosing lesion
A benign radial scar that mimics malignancy on imaging and often warrants excision.
-
Ductal carcinoma in situ (DCIS)
Non-invasive malignant cells confined to the duct — usually detected as microcalcifications on mammography.
-
Invasive ductal or lobular cancer
The two commonest invasive breast cancers — graded, staged and receptor-typed at biopsy.
-
Papilloma
A benign duct lesion that can present with bloody or clear nipple discharge.
-
Lymphadenopathy
Enlarged axillary or supraclavicular nodes assessed and biopsied where suspicious.
-
Red flag: BI-RADS 5 or 6 finding — urgent oncology / MDT referral
A highly suspicious or biopsy-proven malignancy that mandates immediate MDT and oncology input.
Next steps
What comes after the triple assessment.
Every result — benign, high-risk or malignant — has a defined next step, agreed at the breast multidisciplinary team meeting.
-
Reassurance if benign
A concordant benign triple assessment (B1/B2 with matching imaging) can be safely discharged with safety-netting advice.
-
Repeat clinic in 3–6 months
Short-interval imaging follow-up for probably benign (BI-RADS 3) lesions to confirm stability.
-
Surgical excision for high-risk lesions
Excision biopsy for B3 lesions — atypical hyperplasia, radial scars, papillomas and phyllodes tumours.
-
Oncoplastic breast surgery
Wide local excision or mastectomy combined with reconstruction techniques to preserve shape and cosmesis.
-
Neoadjuvant chemotherapy
Systemic therapy before surgery for larger or biologically aggressive tumours to downstage disease.
-
Endocrine therapy
Tamoxifen or an aromatase inhibitor for hormone-receptor-positive disease, tailored to menopausal status.
-
Sentinel node biopsy
Nodal staging with dual dye and radioisotope mapping in invasive cancer with a clinically clear axilla.
-
Multi-disciplinary team review
Every diagnosis discussed at breast MDT — radiology, pathology, surgery, oncology and specialist nurses agree the plan together.
Red flags
When triple assessment is urgent.
Nine presentations that should never wait — each triggers same-week private assessment or the two-week wait NHS pathway.
-
BI-RADS 4 or 5 lesion
A suspicious or highly suspicious imaging category demands biopsy and rapid MDT review.
-
Bloody nipple discharge
Unilateral, single-duct, spontaneous bloody discharge warrants urgent triple assessment.
-
Skin tethering / peau d’orange
Skin dimpling or orange-peel texture suggests underlying malignancy or inflammatory disease.
-
Fixed axillary lymphadenopathy
A hard, fixed or matted axillary node is a significant red flag and needs immediate work-up.
-
Inflammatory breast cancer
Rapid-onset redness, warmth and oedema of the whole breast — a rare but aggressive presentation.
-
Paget’s disease of the nipple
Persistent eczematous change of the nipple-areolar complex — biopsy is mandatory.
-
Male breast lump
Any discrete lump in a man over 50 requires urgent triple assessment.
-
BRCA carrier with new lump
Known pathogenic BRCA1/2 mutation carriers with a new symptom need same-week assessment and MRI.
-
Pregnancy-associated breast cancer
A new lump during pregnancy or lactation must never be dismissed — ultrasound is safe and first-line.
Reading your report
A triple assessment report can look intimidating. It isn’t.
Whatever the finding, the report keeps to the same four parts — P, U/M and B scores that summarise every element.
A quiet reminder
The report is written for your doctor, not for you — and that’s normal.
If you would like us to talk you through it before your follow-up, just ask.
- 01 Header
Indication and risk factors
Your details, presenting symptom, family history and menstrual or menopausal context.
- 02 Clinical
Examination findings (P score)
Documented lump characteristics with a P1–P5 clinical suspicion score.
- 03 Imaging
Ultrasound and mammogram (U and M scores)
Lesion morphology, size and vascularity with U1–U5 and M1–M5 imaging scores — plus BI-RADS category.
- 04 Pathology
Core biopsy (B score) and MDT plan
Histology reported as B1–B5, receptor status where malignant, and the multidisciplinary next step.
Frequently asked
Everything we get asked about triple assessment.
Quick answers on imaging choices, the biopsy itself, results turnaround and the NHS vs private pathways.
-
What is a breast triple assessment?
The gold-standard work-up of a breast lump — clinical examination, imaging (ultrasound and/or mammogram) and, where indicated, an image-guided needle biopsy — combined in a single visit at a one-stop breast clinic.
-
Do I need a mammogram or an ultrasound?
Under 40, ultrasound is the first-line imaging test because dense glandular tissue limits mammographic sensitivity. From 40 onward, mammography and ultrasound are combined. MRI is added in specific situations.
-
Is the core biopsy painful?
It is performed under local anaesthetic and most patients describe pressure rather than pain. Mild bruising for a few days is normal; a small dressing is applied and you can go home the same day.
-
How long do biopsy results take?
Histology from a core biopsy is typically available within 7–10 days. Results are discussed at the breast multidisciplinary team meeting before being shared with you.
-
Is the two-week wait NHS pathway the same as a private one-stop clinic?
The clinical standards are the same — clinical exam, imaging and biopsy where indicated. Private one-stop clinics often condense the assessment into a single visit within the same week, whereas NHS pathways may spread the steps across appointments.
-
What if my triple assessment is benign?
A concordant benign result (B2 histology matching benign imaging and examination) has an exceptionally low false-negative rate. You will be discharged with safety-netting advice and asked to return if symptoms change.
Sources
Guidelines this page draws on.
Reviewed 2026-07-30 by Pulse Atlas Editorial Board (). Next review 2027-07-30.
Related tests
Looking for a different test?
-
Mammography
Digital two-view mammography with tomosynthesis for screening and diagnostic imaging.
Learn more -
Breast ultrasound
High-frequency ultrasound of breast lumps — first-line under 40.
Learn more -
MRI breast
Contrast-enhanced breast MRI for BRCA carriers, dense breasts and problem-solving.
Learn more -
All tests
Browse every test and procedure we arrange.
Learn more -
Endometriosis
Related condition guide.
Learn more -
Menopause
Related condition guide.
Learn more -
Coil IUD IUS Insertion And Removal
Related treatment option.
Learn more -
Colposcopy With Lletz
Related treatment option.
Learn more
In practice, in London
The London pathway for breast triple assessment
With breast triple assessment, the London question is usually about report turnaround and the radiologist reading it — not whether the scan is available. Waiting lists on the NHS for breast triple assessment vary widely by borough and by how the GP letter reads. Privately in London, we can normally offer a slot inside the same week, sometimes within 48 hours if there’s a cancellation. The difference isn’t clinical quality — the consultants are frequently the same faces you’d see on the NHS — it’s the calendar.
A typical private booking for breast triple assessment in London starts with a consultant conversation — sometimes in person on Harley Street or Marylebone, sometimes on video if that suits better. Any imaging or diagnostics happen at a nearby CQC-registered facility, and reports usually land within 24 to 72 hours. The whole loop, from first call to written report, is often done inside a fortnight. For breast triple assessment specifically, the difference between a routine report and a sub-speciality read is where private care earns its keep.
There are a lot of consultants in London who can technically handle breast triple assessment. Fewer who do it week in, week out for the exact question you’re bringing. We spend most of our time working out which is which — and being straight when a different test or a different specialist would serve you better. Everything runs to CQC, GMC and Royal College standards; the choice is about fit, not floor.
Nearby in the library